BACK IN STOCK – 1% STRENGTH ONLY, due to recent regulation changes.
Procaine 1% (Loges or other equivalent brand) 10×2 ml amp (Novocain) [note: image is for illustration only – we dispense this product from a clinical packing of 100 ampoules so you will get in packed on a paper tray)
Administration routes: IM, SC, IC
Local anaesthetic and neural therapy
sterile and pyrogen-free, preservative-free
1 ampoule of 2 ml contains:
Procaine hydrochloride 40 mg
Applications: Any application of neural therapy procedures, anaesthetic, especially in painful, neuritis, neuralgia, such as intercostal, scar pain, and migraine. Rheumatic diseases such as muscular and articular rheumatism, lumbago, sciatica, shoulder-arm syndrome, epicondylitis, myogeloses, headaches of different origins. Paresthesias, and paralysis of various origins. Gonarthrosis, coxarthrosis.
Dosage: The neural therapeutic application should follow the guidelines of the segment and neural therapy. Depending on the indication, unless otherwise prescribed, 0.5-2 ml »Hewedolor-injected procaine 2%” on wheal intracutaneously or subcutaneously, and periarticular, to nerves and tendons, and perinerval. The i.v. Injection is not recommended. The maximum daily dose for adults is 5 Amps »Hewedolor-procaine 2%” (= 10 ml solution for injection).
Application Notes: mixed injection with other injectable solutions is not recommended because of the unpredictable effects of the new drug combination. Unless the administration of several different injection drugs is therapeutically indicated, they are usually injected one after another.
Pharmacology: Procaine is rapidly cleaved by esterases in tissue and is therefore relatively non-toxic but only briefly effective as opposed to lidocaine (“Heweneural 1%”). The degradation occurs in the tissue diethylaminoethanol. This causes a breakdown product of vasodilatation and is thus effective circulation.
Procaine has an analgesic, anti-inflammatory, and antispasmodic effect.
Contraindications: Intravascular injection, allergy to procaine, benzoic acid and sulfonamides. ‘Para’ allergy. Combination with sulfonamides, lack of pseudocholinesterase. Injection into an infected area. 1st Trimester of pregnancy.
Side effects: As with all local anesthetics of the ester-type dose-dependent occur with intramuscular or subcutaneous injection of the following side effects:
Systemic allergic reactions manifesting as urticaria, edema, bronchospasm and anaphylactic shock.
Local allergic reactions in the form of contact dermatitis with erythema, pruritus and blistering. Local reactions in the form of swelling, edema, erythema, eczema papulovesivular, superficial and deep necrosis, hematoma.
In case of accidental intravascular application, the following adverse effects occur (partly dependent on dose and injection speed):
Central nervous system disorders (such as agitation, breathing problems, muscle tremors to generalized convulsions, nausea, vomiting), skin reactions (urticaria, mucosal edema, rash), blood pressure, tachycardia, bradycardia, ECG changes (flattened T waves, shortened ST segment); anaphylactic shock, kidney failure, genital bleeding in postmenopausal women.
Note: Hypotension and tachycardia or bradycardia are often compensated solely by horizontal or slightly head-down position.